Patients with relapsed multiple myeloma treated with carfilzomib (Kyprolis) in combination with low-dose dexamethasone lived twice as long without their disease worsening, demonstrating significant superiority over bortezomib (Velcade) in combination with low-dose dexamethasone. This is according to results of the phase III ENDEAVOR study. The ENDEAVOR study is the first of two head-to-head studies for carfilzomib versus bortezomib, an established proteasome inhibitor, currently approved to treat multiple myeloma.
The primary endpoint of the trial was progression-free survival (PFS), and interim study analysis demonstrated that the median PFS of carfilzomib was 18.7 months versus 9.4 months with bortezomib. In addition to response rate, patients experienced less neuropathy events with carfilzomib when compared to bortezomib.
While PFS with carfilzomib demonstrated positive results, the adverse events reported from the trial are worth mentioning.
Adverse events and on-study deaths were comparable between both arms, but in the ENDEAVOR trial, the rates for cardiac and renal failure were higher in the carfilzomib arm versus the bortezomib arm. Furthermore, there was an increase in the incidence of hypertension and dyspnea in the carfilzomib arm compared to the bortezomib arm.
While data analysis from the trial is still ongoing, complete data results will be presented at the 2015 ASCO Annual Meeting in Chicago.
Are you currently treating multiple myeloma patients in your cancer center? If so, what treatment regimens seem to be demonstrating the best results?